Polymorphism of Beta2-Adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

Table 1

Comparison of baseline clinical and functional data between the two groups of patients.

	GlyGly16	ArgArg16 + ArgGly16	𝑃 value
Number	14	15
Age (years)	34.28 ± 14.97	32.73 ± 8.34	0.73
Duration of disease (years)	16.50 ± 8.10	15.87 ± 9.98	0.92
FVC (% pred)	111.36 ± 15.30	105.93 ± 14.78	0.34
FEV1 (% pred)	100.27 ± 13.07	91.93 ± 14.19	0.11
FEV1/FVC (%)	76.87 ± 9.46	75.07 ± 8.34	0.59
FEF25--75 (% pred)	72.14 ± 23.14	61.80 ± 23.67	0.24
FEV1 changes after salbutamol (%)	9.43 ± 5.40	9.73 ± 7.63	0.90
PC20FEV1 (mg/mL)*	1.93 ± 1.10	1.54 ± 1.26	0.53

Data are expressed as mean ± SD.
*The methacholine challenge test was performed in 11 patients of the GlyGly16 group and in 10 of the ArgArg16 + ArgGly16 group.
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 sec; FEF_25--75: forced midexpiratory flow; PC20FEV1: provocative concentration of methacholine causing 20% fall in FEV1.